Levothyroxine dose prediction post-thyroidectomy for differentiated thyroid carcinoma

Area of Science:

• Endocrinology
• Oncology
• Pharmacology

Background:

• Levothyroxine (L-T4) overestimation is common in overweight/obese individuals.
• Accurate L-T4 dosing is crucial for TSH suppression post-thyroidectomy in differentiated thyroid carcinoma (DTC).

Purpose of the Study:

• To identify optimal body weight metrics for L-T4 dosing in DTC patients.
• To develop an accurate L-T4 dosing model for TSH suppression based on BMI and weight metrics.

Main Methods:

• Retrospective analysis of 385 DTC patients stratified by TSH targets and BMI.
• Linear regression to correlate L-T4 dose with various weight metrics.
• Model validation using a hold-out method and comparison with empirical dosing.

Main Results:

• Higher BMI correlated with higher total L-T4 doses but lower weight-adjusted doses.
• Adjusted body weight was optimal for BMI ≤ 23.9 kg/m², lean body weight for BMI ≥ 24.0 kg/m².
• The new model improved accurate initial L-T4 dose prediction (68.0% vs. 30.2%).

Conclusions:

• A BMI-stratified L-T4 dosing formula using optimized weight metrics enhances accuracy.
• This approach expedites TSH suppression and may reduce adverse events in DTC patients.